What amount sold does Vivorte Inc. report in Form D filings?

The latest linked filings report $8.7M sold across 8 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Vivorte Inc.'s most recent SEC filing?

Vivorte Inc.'s most recent Form D filing was on 2022-07-21.

How many investors does Vivorte Inc. have?

The most recent Form D filing lists 18 investor(s).

What type of securities does Vivorte Inc. offer?

Vivorte Inc.'s SEC Form D filings indicate equity offerings.

Vivorte Inc.

CIK: 0001509210·Biotechnology·LOUISVILLE, KY·Corporation

Reported Sold

$8,744,161

Total Filings

Identified Offerings

Last Filed

Jul 21, 2022

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Jul 21, 2022Form D — New notice

Reported sold: $600,858 · Target: $2,500,000

Rule 506(b)·18 investors

Mar 31, 2021Form D — New notice

Reported sold: $321,080 · Target: $717,120

Rule 506(b)·15 investors

Sep 14, 2020Form D/A — Amendment

Reported sold: $835,001 · Target: $1,730,000

Rule 506(b)·22 investors

Changed: Reported amount sold, Reported investors

Sep 14, 2020Form D — New notice

Reported sold: $894,998 · Target: $927,642

Rule 506(b)·14 investors

Apr 28, 2020Form D — New notice

Reported sold: $991,745 · Target: $1,730,000

Rule 506(b)·20 investors

Oct 3, 2019Form D — New notice

Reported sold: $350,000 · Target: $350,000

Rule 506(b)·5 investors

Nov 29, 2018Form D — New notice

Reported sold: $902,224 · Target: $1,500,000

Rule 506(b)·30 investors

Nov 29, 2018Form D — New notice

Reported sold: $410,000 · Target: $1,500,000

Rule 506(b)·8 investors

Jul 25, 2013Form D/A — Amendment

Reported sold: $4,430,000 · Target: $4,500,000

Rule 506·74 investors

Changed: Reported amount sold, Offering target, Reported investors

Jan 19, 2011Form D — New notice

Reported sold: $1,179,600 · Target: $2,000,000

Rule 506·35 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

20%

Latest reported sold across 8 identified offerings

$8,744,161

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Robert Saunders

Related Person

Appears on 10 filings

Ruth Voor

Related Person

Appears on 10 filings

Michael Voor

Related Person

Appears on 10 filings

Mark Wagner

Related Person

Appears on 8 filings

William Scheessele

Related Person

Appears on 8 filings

Tyree Wilburn

Related Person

Appears on 8 filings

Peter Weiss

Related Person

Appears on 2 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Jul 21, 2022	New	$2,500,000	$600,858	18
Mar 31, 2021	New	$717,120	$321,080	15
Sep 14, 2020	Amendment	$1,730,000	$835,001	22
Sep 14, 2020	New	$927,642	$894,998	14
Apr 28, 2020	New	$1,730,000	$991,745	20
Oct 3, 2019	New	$350,000	$350,000	5
Nov 29, 2018	New	$1,500,000	$410,000	8
Nov 29, 2018	New	$1,500,000	$902,224	30
Jul 25, 2013	Amendment	$4,500,000	$4,430,000	74
Jan 19, 2011	New	$2,000,000	$1,179,600	35

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Accufy Diagnostics, Inc.

Biotechnology

Offering target: $2,000,000

Filed Oct 28, 2026